SynthesisAnnals of global health2020
Survival Rate of Prostate Cancer in Asian Countries: A Systematic Review and Meta-Analysis.
Synthesis in Annals of global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of interventions on the quality of life of cancer patients: a systematic review and meta-analysis of longitudinal research.Health and quality of life outcomes · 2023Pooled it
- Survival Rate and Prognostic Factors of Localised Prostate Cancer in Southeast Asian Countries: A Systematic Review with Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Survival outcomes in prostate cancer patients treated at an Indian tertiary care centre.BJUI compass · 2026Article
- RAB40C regulates SNX9 stabilityCentral-European journal of immunology · 2026Article
- The Burden of Genitourinary Malignancies in Southeast Asia from 1990 to 2021.European urology oncology · 2025Article
- Identifying drug targets and evaluating KLK3-targeted inhibitors for prostate cancer using in-silico and in-vitro approaches.Medical oncology (Northwood, London, England) · 2025Article
- First validation of the Prostatype® P-score in an Asian cohort: Improving risk stratification for prostate cancer.BJUI compass · 2025Article
- Telomerase related molecular subtype and risk model reveal immune activity and evaluate prognosis and immunotherapy response in prostate cancer.Cancer cell international · 2024Article
- XRCC1 and XPD polymorphisms: clinical outcomes and risk of prostate cancer in Bangladeshi population.Molecular biology reports · 2024Article
- Advances in multiparametric magnetic resonance imaging combined with biomarkers for the diagnosis of high-grade prostate cancer.Frontiers in surgery · 2024Review
- A Novel DNA Aptamer Probe Recognizing Castration Resistant Prostate Cancer in vitro and in vivo Based on Cell-SELEX.Drug design, development and therapy · 2024Article
- Financial burden of prostate cancer in the Iranian population: a cost of illness and financial risk protection analysis.Cost effectiveness and resource allocation : C/E · 2023Article
- Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.Scientific reports · 2023Article
- Burden of esophageal cancer between 2010 and 2019 in Asian countries by geographical region and sociodemographic index: A comparison with global data.Thoracic cancer · 2023Article
- Overcoming barriers to prostate cancer care in the Philippines.Frontiers in urology · 2023Article
- CHMP4C as a novel marker regulates prostate cancer progression through cycle pathways and contributes to immunotherapy.Frontiers in oncology · 2023Article
- Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements.Asia-Pacific journal of clinical oncology · 2022Article
- Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.British journal of cancer · 2022Review
- Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview.The world journal of men's health · 2022Review
- Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is one of the most common health issues among men, especially older men. In recent years, incidences of prostate cancer is increasing. Objective: The aim of this study was to provide a comprehensive estimate of the survival of prostate cancer in Asian countries. Methods: We searched five international databases including Medline/PubMed, Scopus, Embase, Web of Knowledge and ProQuest until June 1, 2018. The Newcastle-Ottawa Quality Assessment was used to evaluate the quality of selected papers. The review protocol was registered in PROSPERO (CRD42019117044). Results: A total of 714 titles were retrieved. Thirty-seven studies met the inclusion criteria. Based on the random-effect model one-year, five-year and ten-year survival rate of prostate cancer were 81% (95% CI 77.8-84.2), 61.9% (95% CI 59.5-64.3) and 36.2% (95% CI 9.2-63.2) respectively. Survival rates based on HDI level for five-year were 30.07, 43.43 and 70.84 percent for medium, high and very high levels, respectively. Conclusion: According to the results of our study, the prostate cancer survival rate in Asian countries is relatively lower than in Europe and North America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.